Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | (3.7%) | (11.5%) | (22.4%) | (40.6%) | (41.6%) | (50.6%) | (65.4%) | (82.7%) | (155.5%) | (162.9%) | (109.5%) | (89.1%) | (79.5%) | (31.2%) | 28.2% | (60.2%) | (71.5%) | (98.3%) | (19.0%) | (22.0%) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is (58.0%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for Summit Therapeutics Inc. have been (129.4%) over the past three years, and (116.6%) over the past five years.
As of today, Summit Therapeutics Inc.'s Return on Capital Employed (ROCE) is (58.0%), which is lower than industry median of (51.0%). It indicates that Summit Therapeutics Inc.'s Return on Capital Employed (ROCE) is Bad.